EASL 2015 HCV Abstract Choices: Dr. Gaglio

Posted on April 16, 2015

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book.

Abstract G15
The Association of Sofosbuvir and Daclatasvir For Treating Severe Recurrence of HCV Infection After Liver Transplantation: Results From a Large French Prospective Multicentric ANRS CO23 CUPILT Cohort

Coilly A, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LO1
Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir For Treating HCV GT1 Infection in Patients with Severe Renal Impairment or End-Stage Renal Disease: The RUBY-I Study

Pockros PJ, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LO3
Safety and Efficacy of the Combination Daclatasvir–Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER

Pol S, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LO8
Daclatasvir, Sofosbuvir, and Ribavirin Combination For HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study

Poordad F, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LP02
C-SURFER: Grazoprevir Plus Elbasvir in Treatment-Naïve and Treatment-Experienced Patients With Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease
Roth D, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LP03
Safety and Efficacy of Short-Duration Treatment With GS-9857 Combined With Sofosbuvir/GS-5816 in Treatment-Naïve and DAA-Experienced Genotype 1 Patients With and Without Cirrhosis
Gane EJ, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LP06
Sustained Virologic Response After ACH-3102 And Sofosbuvir Treatment For 8 or 6 Weeks: a Phase 2 “PROXY” Study
Gane E, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LP07
Simeprevir (SMV) Plus Daclatasvir (DCV) and Sofosbuvir (SOF) In Treatment-Naïve and -Experienced Patients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease: Interim Results From the Phase II Impact Study
Lawitz E, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LP13
Effect of Long Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension
Afdhal N, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.

Abstract LP15
Separate and Combined Effects of Obeticholic Acid and Weight Loss in Nonalcoholic Steatohepatitis (NASH)
Hameed B, et al. The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.


No Replies to "EASL 2015 HCV Abstract Choices: Dr. Gaglio"


    Join the discussion

    Some html is OK